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Medical Care of Costs and
AIDS in New Implications
England:
Stewart J. Landers, J.D. ,M.C.R
George R. Seagelll, M.RH.
This article presents an overview ofcost issues related to AIDS. Datafrom the Massachu-
setts Cost ofAIDS Study are combined with epidemiological projections to estimate the
cost oftreating people diagnosed with AIDS in New England. Aggregate inpatient, ambu-
latory, and home care costs are estimated to be $96. 9 million and $524. 8 million through
1987and 1991, respectively. These estimates represent a relatively smallpercentage of
total health care costsfor all illnesses over the same time period.
The authorsfind that the cost oftreating AIDS does not affect all health care providers
uniformly and therefore argue that appropriate measures must be developed to assist those
impacted disproportionately. Reduction ofinpatient hospital days through the creation of
subacute care centers, subsidyprogramsfor medical care providers serving large numbers
ofuninsured or underinsuredAIDSpatients and education to prevent new cases are rec-
ommended to continue the availability ofmedical careforpeople with AIDS.
The rapidly growing number ofAIDS cases in the United States has generated an
increased interest in the cost of treating patients with HTV infection. Projections of
future cases — the number is expected to exceed 270,000 for the nation as a whole by
1991 — are a warning to legislators, insurers, employers, health care and policy planners,
hospital administrators, private practitioners, and health care activists to prepare for the
economic impact of AIDS. 1 One of the most frequent questions asked of public health
officials regarding treatment programs for people with AIDS is, How much will it cost?
The health care needs of people with AIDS are usually considered from the perspective
either of cost or of utilization. With regard to cost, the key questions are, How much will
it cost? Who will pay the cost? To what extent can society afford to pay the cost? From the
perspective of utilization, the important issues are related to the availability of resources:
What types of resources do AIDS patients need? Are these resources available currently?
Will they be available to meet future demand?
Stewart J. Landers is project director ofthe Massachusetts Cost ofAIDS Study. George R. Seage III is the senior
AIDS epidemiologistfor the Boston Department ofHealth and Hospitals and is principal investigator ofthe
Massachusetts Cost ofAIDS Study.
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Questions about cost and utilization of services merge in the areas of planning and
budgeting. While there is little doubt that the resource utilization and the accompanying
cost of treating people with AIDS are large and will get significantly larger, it is also
likely that, given adequate planning, cost-effective resources can be identified to meet
this need.
In this article, the authors stress that information about cost is critical to planning for
the provision ofAIDS care. The text is divided into three main sections. The first section
reviews information currently available on the cost of services in New England, specifi-
cally in Massachusetts. Inpatient, ambulatory, and home care costs are described. The
indirect costs of care are discussed. These indirect costs include some hidden costs that
may represent the largest costs of the epidemic. Changes in the cost of treating people
with AIDS are discussed. The section concludes with estimates of the cost of treating
AIDS in New England up to 1988 and cumulatively through 1991
.
The second section describes the payer mix ofAIDS patients and the anticipated impact
of the projected AIDS crisis on each type of payer. People with AIDS must do battle with
private and public insurance programs to receive coverage for their care. Public and pri-
vate insurers, as well as hospitals providing free care, struggle to act responsibly in the
face of this epidemic without overextending themselves financially.
The third section discusses the implications of health care costs in planning for the
provision of health care for people with AIDS. The section addresses issues of insurabil-
ity, cost containment, and prevention, and targets specific areas where planning is neces-
sary to provide humane, comprehensive, and quality care to persons with AIDS.
The Cost of Treating Patients with AIDS
The initial report on the cost of treating patients with AIDS estimated a cost of $147,000
per patient. 2 Subsequent studies in San Francisco and Massachusetts found that medical
care costs were significantly lower. 3 4 A review of cost studies by the federal Office for
Information Technology reported lower costs in studies from Maryland, New York, New
Mexico, Alabama, Minnesota, Florida, and California. 5 Research from a hospital in Vir-
ginia6 and the first two national studies with a wide sample of data7 8 provide further con-
firmation that direct medical care costs are lower than the initial estimate, probably in the
range of $20,000 to $60,000.
Cost in Massachusetts
In Massachusetts, a study to determine the costs of treating AIDS was begun in February
1985. The study was sponsored by the state Department of Public Health and was con-
ducted by the public health AIDS program of the Boston Department of Health and Hospi-
tals. In that study, the authors of this article and their colleagues evaluated forty-five
AIDS patients seen at the New England Deaconess Hospital between March 1984 and
February 1985. 9
Inpatient and outpatient medical and billing records were reviewed to obtain cost, utili-
zation, and demographic data. Data from the Massachusetts Rate Setting Commission
were used to convert inpatient charges to costs. Charges for ambulatory care were con-
verted to costs through the use of Blue Cross customary reimbursement rates.
On the basis of these data, the researchers calculated an average hospitalization cost of
$14, 189 and an average length of stay of 21 days per hospitalization. To answer a variety
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of questions, the authors also calculated cost per patient per annum (twelve-month period)
as $46,505, and costs per case, from diagnosis to death, as $50,380. 10
Analyses of the data also yielded the number of hospitalizations per patient as 1.6; hos-
pitalizations per patient per annum, 3.3; hospital days per patient, 33; and hospital days
per patient per annum, 62.
Components ofInpatient and Ambulatory Care
In the aforementioned cost study, the researchers analyzed the components of inpatient
and ambulatory care to determine where the medical expenses of treating AIDS patients
are concentrated. The results of this analysis (table 1) show that inpatient costs, constitut-
ing 89 percent of total costs incurred by AIDS patients, are dramatically higher than am-
bulatory costs.
Total ancillary services, including laboratory services, were responsible for 47.9 per-
cent of all inpatient care costs for the patients with AIDS studied. This percentage for
ancillary services is not unusual for patient care costs generally. However, the high labo-
ratory component of ancillary services is greater for AIDS patients than for non-AIDS
patients. Room and board (routine and intensive care) and laboratory services comprised
the two largest categories of cost, representing 45 and 22 percent, respectively, of total
inpatient care costs.
Cost for laboratory services and cost of professional services accounted for 56 and 16.9
percent, respectively, of all ambulatory care costs. The large percentage of cost in labora-
tory services is related to the close monitoring of patients' immune status for diagnostic
and palliative purposes.
Home Care and Support Services
Very few studies have analyzed both the cost and the cost-effectiveness of services that
allow people with AIDS to spend more time at home and, presumably, less time in acute
care settings. However, a study of thirty-seven pediatric AIDS cases in New York City
identified 1,909 hospital days that the researchers labeled "social admissions" — that is,
patient days in acute inpatient care facilities resulting from lack of appropriate available
placement. 11 These so-called social admissions represented 31 .2 percent of hospital days
for this cohort of pediatric AIDS cases. Thus, if adequate services were available outside
the hospital, the number of hospital days could be drastically reduced for this cohort.
A San Francisco study of both paid and volunteer home care services showed that home
care was significantly less expensive than hospital-based care. 12 Among the resources
evaluated was a home-based hospice program. This program provided a range ofhome
care services to persons with AIDS which enabled them to spend most of the duration of
their illness, including the terminal stage, at home. For the 165 persons with AIDS who
received care under this program, the study found that they required an average of 47
hospice days per person, at an average cost of $4,401 per patient. The average cost per
day of hospice care was $94, compared to an inpatient cost per day at San Francisco Gen-
eral Hospital of $773. 13 Additional data from San Francisco estimate the cost of acute
inpatient care at $800/day; subacute care at $500/day; skilled nursing facility at $300/
day; residential hospice at $100/day; and nonmedical group residence at $50/day. 14
To evaluate home care needs and utilization, clients of the AIDS Action Committee of
Massachusetts were surveyed. 15 A questionnaire was mailed in the spring of 1986 to 115
clients of the AIDS Action Committee and was returned by 43 individuals. The purpose of
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Table 1
Total Cost per Patient for AIDS Medical Care*
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*George R. Seage III, Stewart Landers, et al., unpublished data from study of cost of treating
45 AIDS patients at New England Deaconess Hospital 1984-85.
the questionnaire was to determine the average weekly utilization of home care services.
The results indicate that 65 percent of respondents used or needed some home care serv-
ices. The researchers determined a mean utilization cost of $107 per week, applying Blue
Cross reimbursement rates to estimate the cost of these home care services. Assuming
that persons with AIDS receive home care except when they are hospitalized, the cost of
home care services for a person with AIDS from diagnosis to death may be estimated to
be $4,985. 16
This figure may be based on an underestimation ofhome care utilization. Those indi-
viduals needing the greatest amount of care were the least likely to respond to a question-
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naire. However, the estimate is almost identical to the estimated cost of home-based hos-
pice care in San Francisco and may be used as a rough approximation of home care costs.
A thorough, population-based study of the utilization of home care health services by
AIDS patients needs to be performed.
Indirect Costs
Scitovsky and Rice have divided the indirect costs of AIDS into two types: morbidity
costs (productivity lost on account of illness) and mortality costs (future earnings lost for
those who die prematurely). 17 They estimated the total direct and indirect cost ofAIDS in
the United States in 1985 alone to be $4.8 billion. Of this cost, the researchers calculated
$3.9 billion, or 81 percent, as indirect costs. Thus, while indirect costs are less obvious in
terms of impact upon the health care system, the overall economic impact of such indirect
costs is immense.
Mortality costs account for 94 percent of indirect costs. These costs are very high,
owing to the young age ofAIDS patients and the associated large numbers of years of life
lost. Not included in this accounting is the fact that many persons with AIDS may not pay
premiums to health insurance, taxes, Social Security, and so on, during what are usually a
person's most productive years.
Other indirect costs related to the cost of AIDS include added infection control precau-
tions, nursing care, and supplies, as well as complex case management services. 18 The
difficulty of caring for AIDS patients consists in increasing personnel costs, owing to the
need for additional support services for personnel. This article will not include the indi-
rect costs ofAIDS in its projections of direct medical care costs in New England.
Changes in the Cost of TreatingAIDS
The cost of providing medical care to a person with AIDS is not static. There is evidence
that the cost may be declining. New and costly therapies for persons with AIDS, as well
as experience in the treatment ofAIDS, will affect the cost of care.
Evidence ofreduction in cost. In July 1985, the study of the cost of treating persons
with AIDS in Massachusetts expanded to include five hospitals and to evaluate patient
utilization over the two-year period March 1984 through February 1986. 19 Two hundred
and forty patients were enrolled over the two-year period. This cohort represented 55
percent of all AIDS patients alive in Massachusetts during the study period. The cohort
was representative of all AIDS patients reported to the Massachusetts AIDS Surveillance
Program with regard to risk group status, gender, geographical distribution, and race.
Preliminary data on cost over the two-year period showed a decline in total inpatient
and outpatient cost from year one to year two at each of the five hospitals studied. The
researchers attributed the observed decrease both to shorter lengths of stay (mean reduced
from 19.2 days/hospitalization to 15.7 days/hospitalization) and to a decrease in the mean
number of hospitalizations (mean reduced from 2.2 hospitalizations/patient to 1 .9 hospi-
talizations/patient). Future analysis of these data will attempt to evaluate additional fac-
tors related to the decline in cost, such as the availability of support services and home
care programs.
The effect on cost ofALT. As antiviral and other therapies are developed, the direct
medical care cost of treating AIDS is likely to change. One therapeutic agent that may
have a significant impact on cost of care is the drug Azidothymidine (AZT). It is uncer-
tain whether use of this drug, which has been shown to decrease the frequency of life-
threatening pneumonia in AIDS patients, will increase or decrease utilization of health
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care services. 20 AZT may reduce the length of stay for AIDS-related hospitalizations and
the overall number of hospital days for AIDS patients, by decreasing the severity of op-
portunistic infections. AZT may also keep AIDS patients healthier longer and allow them
to continue working longer.
On the other hand, by allowing patients to survive more bouts of Pneumocystis carinii
pneumonia (PCP), AZT may result in more lifetime hospitalizations and an increased
number of total hospital days. In addition, physicians may become more aggressive in
their treatment, knowing there is a drug that may significantly extend the patient's life
once any immediate crisis is forestalled.
One thing is certain: AZT is an expensive drug. A one-year supply ofAZT is currently
estimated to cost between $8,000 and $10,000. :i Once on AZT, an AIDS patient needs to
continue taking the drug as long as he or she is alive, unless serious side effects occur.
Experience with AIDS patients. The extent of an institution's experience with AIDS
patients may alter the cost of services to persons with AIDS for a number of reasons,
including familiarity with the disease; adoption of an oncological modality of treatment;
and recognition of the particular out-of-hospital services that AIDS patients may require.
The lack of familiarity with the care required by persons with AIDS may lead to unnec-
essary cost expenditures. A report on the provision of medical care at U.S. public and
private teaching hospitals found that 15 percent of responding hospitals had not yet
treated an AIDS patient.- Familiarity with the care and support that persons with AIDS
require will reduce the number of hospital days, the use of intensive care, and the applica-
tion of unnecessary diagnostic techniques.
As AIDS is a new and thus far terminal illness, AIDS care may utilize a range of differ-
ent treatment modalities. For example, an alternative to the inpatient hospital model is the
oncological or hospice model. This model, developed for terminally ill cancer patients,
attempts to maximize comfort for the afflicted individual and rmnimize aggressive or
intrusive diagnostic and therapeutic measures. AIDS patients receiving hospice care are
much less likely to be placed under intensive care — an unpleasant (albeit potentially life-
prolonging) and costly form of care.
The availability of support services and home care can make a difference in the length
of hospitalizations and the overall cost. In some cases, discharge planners need to famil-
iarize themselves with the services and support groups already available to persons with
AIDS. However, the absence of such services in many local communities may prevent the
implementation of an effective and realistic home care plan.
Estimating Cost in New England
For purposes of estimating direct medical care costs per case, the authors have combined
the mean inpatient and ambulatory cost per case, $50,380, and the mean estimated home
care cost, $4,985. Our estimated total direct medical care costs per case are $55,365.
The number of AIDS cases diagnosed to date in New England is based on case reports
to the Centers for Disease Control (CDC) by the six New England states as of November
23, 1987 (see table 2). Nationally, more than 270,000 cases are expected by the end of
1991 . Massachusetts has consistently reported 2 percent of the national cases, and this
percentage is used to estimate the case load in Massachusetts cumulatively through 1991
.
Projections for the other five New England states are based on the total number of cases
each state has reported cumulatively to November 23, 1987. and the percentage of New
England cases each such total represents. Using these calculations, the total direct medi-
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cal care cost is $524.8 million for persons with AIDS diagnosed in New England during
the ten-year period 1981 to 1991.
Who Will Pay? A Look at the Payers
With an estimate of $524. 8 million needed to pay for the direct medical cost of treating
persons with AIDS in New England through 1991 (see table 2), the most important ques-
tions are, Who is and who will be paying for this, and who will pay in the future? The
simple, if somewhat naive, answer, of course, is that we all pay for the cost of treating
AIDS, either through health insurance premiums, federal and state tax dollars for Medi-
care and Medicaid, or local tax revenue that provides services to the uninsured or reim-
bursements to hospitals for free care and bad debt. The reason this point of view is naive
is that the exact payer mix matters greatly to each potential payer. Insurers wish to reduce
their exposure to high costs; holders of private insurance policies do not want their premi-
ums to rise; and government health care budgets need to remain responsive to a wide
variety of political interests. In essence, AIDS costs highlight the classic confrontation
between the private versus the public sector.
Analysis of the payer mix is key to measuring the impact of policies that will shift the
cost of caring for AIDS patients among payers. The Massachusetts cost study found that
47 percent of people with AIDS had Blue Cross, 18 percent had commercial insurance,
18 percent had Medicaid, and 18 percent had no insurance. 23 These data differ from the
data presented by Andrulis and Beers et al. in their nationwide study. They reported that
for hospitalizations in the Northeast region, only 12 percent were reimbursed by private
insurance. Instead, 65 percent of patients had Medicaid, 17 percent had no insurance, and





















Massachusetts 997 (57.0%) 5,400 55.2 299.0
Connecticut 521 (29.8%) 2,822 28.8 156.2
Rhode Island 105 (6.0%) 569 5.8 31.5
Maine 57 (3.3%) 309 3.2 17.1
New Hampshire 49 (2.8%) 265 2.7 14.7
Vermont 21 (1.2%) 114 1.2 6.3
524.8
*Costs include hospital inpatient, hospital outpatient, and home care costs.
Note: Projections are likely to vary by as much as 50 percent; any variation between these projections and those
found in other articles is due to different assumptions about the number of infected persons, the spread of infection,
and the rate at which those infected will progress to AIDS.
*AIDS Weekly Surveillance Report — United States, United States AIDS Program, Center for Infectious Diseases,
Centers for Disease Control, November 23, 1 987, 2.
bW. M. Morgan and J. W. Curran, "Acquired Immunodeficiency Syndrome: Current and Future Trends," Public
Health Reports 1 01 , no. 5 (September-October 1 986): 461
.
cCosts data are based on George R. Seage III, Stewart Landers, Anita Barry, et al., "Medical Care Costs of AIDS in
Massachusetts," Journal of the American Medical Association 256, no. 22 (December 12, 1986): 3107.
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The wide discrepancy is due to the difference between the two cohorts. The initial Mas-
sachusetts study was comprised predominantly of white, gay men, most of whom were
working at jobs that provided health insurance at the time they became ill. Andrulis and
Beers et al. studied costs at public hospitals and teaching hospitals, and their Northeast
region includes New York and New Jersey as well as New England. The number of per-
sons with AIDS in New England who rely on the public health system may range from 36
percent to almost 90 percent.
Private Insurers
Concern about AIDS costs is not uniform among private insurers. Some private payers
are devising strategies to reduce their exposure to AIDS-related costs. A quick look at the
rise of widespread health insurance, as well as its recent decline, sheds light on the con-
cerns of the industry.
The growth of health insurance in the United States from the time of World War II to
the present is well documented by Rashi Fein, an expert in medical economics at the
Harvard School of Public Health:
[By 1977,] over 80 percent of total health insurance premiums went for the purchase
of group coverage and over 95 percent of all group insurance was provided in the
employment context. Furthermore, almost 90 percent of all U.S. employees worked
in firms that provided health insurance plans and over 90 percent of employees in
those firms were eligible for the insurance. 25
However, Fein also notes:
In 1977 over 99 percent of workers in firms with over 1 ,000 employees had an em-
ployment-related health insurance plan, compared with only 55 percent of workers in
firms with 25 or fewer employees. ... In general, workers in smaller and nonunion-
ized firms were less likely to have employment-related group coverage. 26
Group health insurance is usually provided without any physical exam or laboratory
testing. After a fixed waiting period, the employee is covered regardless of any preexist-
ing conditions he or she may have. As a member of a group insurance plan, an individual
cannot be denied coverage as a result ofHIV testing or other prescreening method em-
ployed by insurers for persons seeking individual coverage.
Under the Consolidated Omnibus Budget Reconstruction Act of 1985 (COBRA), per-
sons covered by group health insurance policies in companies of twenty or more employ-
ees have the right to continue insurance for a period of eighteen months following
termination of employment. 27 Individuals must pay the full cost of premiums. COBRA
also requires that individuals are informed of this right, which enables AIDS patients to
prolong the time period during which their financial resources are protected from the cost
of high medical expenses.
In the 1980s, a significant decline in the availability of group health insurance has oc-
curred. To protect against rising costs, employers frequently exclude family members
and part-time employees from group health policies or require higher co-payments, leav-
ing fewer individuals covered by insurance.
Furthermore, a growing number of companies, especially larger firms, no longer offer
commercial policies and are self-insuring. Eighty-five percent of firms with more than
forty thousand employees and 70 percent of firms with between twenty and thirty thou-
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sand employees are now self-insured. 28 Self-insured groups are covered under the federal
Employee Retirement Income Security Act (ERISA) and are exempt from state regula-
tion. There has been no federal initiative to protect insurance coverage for persons with
AIDS; therefore, employers that are self-insured have greater discretion regarding deci-
sions to test for the AIDS antibody or to not cover AIDS at all. In addition, because these
employers are not subject to state attempts to pool higher health insurance risks, they
undermine the limited experimentation with shared risk pools.
Health Maintenance Organizations (HMOs), a relatively new entrant into the health
care market, have shaped health care policy significantly. HMOs are concerned that HIV-
antibody-positive persons with a choice of insurers will select HMOs to reduce the high
co-payments required by many traditional health insurance policies.
Public-Sector Insurance
The reduced availability of private health insurance underscores the importance of Medi-
caid as an insurer of last resort for AIDS patients in New England. Medicaid eligibility is
dependent upon income and assets. If a person has assets in his or her name, those re-
sources must be depleted in order for that individual to qualify. States have a wide variety
of criteria for Medicaid eligibility. For example, Andrulis and Beers et al. found that only
15 percent ofAIDS cases in the South are paid for by Medicaid. 29 This figure is attributed
to the restrictive Medicaid eligibility requirements common among southern states.
Individuals under age sixty-five become eligible for Medicare after they have received
Social Security Disability Insurance (SSDI) for twenty-four consecutive months, fol-
lowed by a processing period of three to five months. However, the median conditional
probability of survival from date of diagnosis with AIDS is 347 days. 30 Thus, most per-
sons with AIDS never qualify for Medicare. In 1985, Massachusetts determined that an
AIDS diagnosis is a presumptive disability, which qualifies persons with AIDS for SSDI.
However, with the recently expanded case definition, certain AIDS diagnoses, including
wasting syndrome and dementia, no longer automatically qualify an individual for SSDI.
Currently, Medicare pays for the care of approximately 1 to 2 percent of AIDS patients
in Massachusetts, but it could pay for more. There exists a waiver of the two-year Medi-
care waiting period for individuals with certain types of renal disease. If a similar waiver
were available for AIDS patients, the cost of treating them would shift dramatically from
Medicaid to Medicare, and consequently from the state to the federal government. Fur-
ther analysis is necessary to demonstrate the magnitude of this cost shift if the waiting
period were eliminated or if it were reduced to six, twelve, or eighteen months.
Implicit in a state-controlled program is the power to determine what will or will not be
covered. Such decisions are likely to reflect political as well as medical realities. The
decision of a Medicaid program to pay for AZT, for example, is likely to depend as much
on political will as on economics. Medicaid in Massachusetts, as in most states with large
and visible advocacy groups representing persons with AIDS, has decided that it will pay
for AZT.
Free Care
Despite the availability of Medicaid and the advent of client advocates to help people
enroll in publicly funded programs, many individuals continue to fall through the cracks
and seek medical care without any insurance coverage. In Massachusetts, a reimburse-
ment system (Chapter 572) was established to cover hospital losses resulting from free
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care. The system, which expired October 1, 1987, allowed hospitals to set charges in
excess of expenses in order to cover free care. Some other New England states do not
reimburse hospitals for free care.
A large number of persons with AIDS do not have health insurance and therefore tax
the system to reimburse free care. Thus, the AIDS epidemic has a disproportionate im-
pact on those hospitals seeing the greatest numbers of AIDS patients. Boston hospitals
reported 79 percent of Massachusetts cases, although only 47 percent of Massachusetts
cases actually reside in Boston. The concentration of cases at these hospitals invalidates
the equations previously used to compensate these institutions.
The AIDS epidemic will increase the need for services among uninsured, underinsured,
and Medicaid patients. For hospitals that continue to provide care for indigent patients,
this epidemic will mean a rise in free care. Government must ensure the willingness and
financial ability of hospitals to care for indigent patients.
Issues Affecting Cost and Treatment
The direct medical care costs of treating persons with AIDS present a challenge to the
fiscal planning efforts of health care planners in New England. In relation to overall na-
tional health expenditures, the actual cost of treating persons with AIDS is small. Sci-
tovsky and Rice estimate that in 1991 , AIDS will represent 1 .4 percent of estimated
national medical care costs. 31 This relatively small percentage could be absorbed if it were
distributed evenly across all insurers and providers of care. However, in order to tame the
rise in health care costs, access to health care has become unevenly distributed in society.
The health care industry is developing new methodologies for cost containment. In the
process, certain population groups — such as family members — have effectively been
denied access to medical care; some employers provide very limited options that deny
employees full coverage. These disenfranchised groups are already taxing the public
health care system. With the addition ofAIDS treatment, certain providers may be totally
crippled.
A new movement to protect access to health insurance is developing nationwide in
response to the cost containment practices in the health care industry. Advocates of com-
passionate health care must couple arguments for wider access to care with plans for cost
containment. Without cost containment, plans to increase access to health insurance do
not appear to be politically viable. In Massachusetts, Governor Dukakis has led a move-
ment for universal health insurance but as of this writing has not succeeded in passing
legislation for this purpose. 32
Until some form of universal health insurance is enacted, the marketplace for health
care will become increasingly restrictive. For persons with AIDS or who are infected
with HIV, the available options may become fewer as the need for insurance becomes
greater. In the next section, we look at the developments in health insurance which affect
persons with AIDS or at risk for AIDS. The section concludes with suggestions for reduc-
ing the adverse economic impact ofAIDS on the health care system.
Developments in Health Insurance
Various developments in health insurance may alter the source of payments as well as the
cost of care. HIV antibody screening will shift responsibility for the cost of caring for
AIDS from private insurance to the public sector. Insurance coverage of subacute care
facilities will shift medical care services to less cost-intensive alternatives. Shared risk
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pools are one mechanism for maintaining private insurer involvement in the care of per-
sons with AIDS.
HIVantibody testing. Insurers have sought the right to screen applicants for health
insurance for evidence of HIV infection. Screening for HIV antibody status has not been
initiated for group health insurance, since no eligibility screening practices are currently
in place for group plans. If insurance losses due to AIDS become unmanageable, insurers
may increase efforts to screen for HIV infection under group plans. In Massachusetts,
hearings on proposed regulation of the use of the HIV antibody test reflected widespread
consensus among all constituencies, except insurers, against the use of the test for health
insurance eligibility. 33 This view is consistent with a widespread opinion in Massachusetts
that health insurance is a necessity and should be considered a basic individual right.
The Massachusetts Division of Insurance had, until September 1, 1987, prohibited
insurers from using the HIV antibody test at all. The division then promulgated and
adopted regulations allowing limited use of the test for individual life and disability insur-
ance plans. The regulations also provided for limited confidentiality of test results and for
required counseling of persons who tested positive. Upon challenge by the insurance
industry, a preliminary court decision held that the regulation is an invalid exercise of
power by the insurance commissioner. 34 At the present time, it is uncertain whether courts
will recognize an administrative or regulatory ban on antibody testing without special
enabling legislation.
Fairness and excessive losses are the main arguments offered by insurers to justify
screening out HIV-infected individuals for health insurance. Insurers argue that if they
are forced to assume the high cost of insuring HIV-infected persons, individual premiums
will increase. Any rise in premiums, they contend, will force individuals who are strug-
gling to maintain individual policies to give up those policies. Therefore, if the insurabil-
ity of individuals with HIV infection or AIDS is protected, other individuals may be
deprived of health insurance. Furthermore, since insurance companies currently refuse
insurance to "bad risks" — such as former cancer patients, women with certain types of
benign cysts, 35 and others — insurers argue it would be unfair to insure HIV-infected
persons who are comparably bad risks. However, state governments, for public policy
reasons, have successfully constrained insurers from using other tests, including those
which indicate the presence of sickle cell, Tay-Sachs, and hemoglobin C traits. 36
Insurers are so adamant about the preceding arguments that to avoid state regulations
against HTV testing, they are attempting to use other methods to screen applicants without
using HIV testing per se. Some insurers have already utilized screening criteria as diverse
as marital status, residence or zip code, medical history, beneficiary, and living arrange-
ments to screen out persons who are potentially at risk for AIDS. 37
The use of HIV screening threatens to create a class of individuals likely to be subject to
discrimination in various aspects of life. Persons with AIDS or who are perceived to be at
risk for AIDS have suffered discrimination in employment, housing, accommodations,
and parental rights. 38 Use of HIV screening by insurers increases the risk of discrimina-
tion, particularly since safeguards to protect the confidentiality of information collected
by insurance companies are inadequate. The failure of the federal government to protect
individuals from discrimination on the basis of their HIV antibody status creates an atmos-
phere that discourages use of the antibody test.
Coverage ofhome care, hospice, and otherforms ofsubacute care. Strategies need to
address the coverage of cost-effective methods of caring for AIDS patients, including
home care, hospice, group residences, skilled nursing facilities, and subacute care units.
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As noted in the first section of this article, the daily costs of care for these services are
significantly lower than acute inpatient cost.
Medicaid programs in each state may apply for a waiver that would allow the program
to develop more effective reimbursement plans for a particular disease. New Jersey has
received such a waiver for AIDS and has established a system for reimbursing those out-
of-hospital services which are required to care for patients with AIDS in the most humane
and cost-effective manner.
Beginning in FY' 87, Massachusetts allocated funds to eight home health care agencies,
in order to assist the agencies in developing services for persons with AIDS. The grants
have been used for staff training, education, and outreach programs. The grant recipients
have argued that insufficient reimbursement is still a major impediment to effective deliv-
ery of services to persons with AIDS, and have looked to insurers, primarily Medicaid, to
reevaluate the services for which home health care agencies may seek reimbursement.
Case management is another approach that is receiving increased attention as a cost-
effective way of coping with specific medical problems. Under this approach, a case
manager helps develop a strategic plan for the patient. For example, in the case ofAIDS
patients, a case management approach may involve educating the family and friends in
order to help them overcome fears of the disease and help them enable the patient to re-
main at home as long as possible. Blue Cross of Massachusetts has adopted a case man-
agement system for elderly patients but has not implemented the program for persons
with AIDS. A study of the effectiveness of case management for AIDS patients is under
way at the AIDS Medical Resource Center in Illinois. 39
Shared risk pools. The problem of "uninsurables" is not a new one, and, as indicated
earlier, other classes of individuals have had difficulty obtaining health insurance. In
order to maintain private insurer involvement in coverage of high-risk individuals, thir-
teen states have passed legislation establishing risk pool programs. 40 Under these pro-
grams, private insurers contribute to a pool that provides health insurance to individuals
at high risk for various diseases. The premiums are generally higher than normal, and
government subsidies keep them within an affordable range. The programs have not been
very successful. In 1986, the seven operating risk pools enrolled only twenty-one thou-
sand people, and all but one of the pools lost money. 41 The addition of AIDS patients as
beneficiaries of the pool would exacerbate this situation further.
Access to insurance is hampered for persons with AIDS not only because of unavaila-
bility, but also because of cost of premiums, since an AIDS diagnosis is often accompa-
nied by loss of employment and of the ability to pay for insurance. Therefore, shared risk
pools alone are unlikely to solve the problem of providing health insurance for persons
with AIDS, and may need to be combined with a subsidy or coupon-type program to
allow persons with AIDS to purchase such insurance.
Suggestionsfor Managing the Cost ofCaringfor People
with AIDS
Reduce acute inpatient care days. Acute inpatient care constitutes the largest single
component of the direct medical care costs of AIDS patients. It is necessary to reduce
acute inpatient care as much as possible without compromising the quality of care each
patient receives. Reduction of inpatient care may be accomplished by establishing an
organized, well-trained, and reimbursable continuum of care.
Physicians must be trained to recognize the opportunistic infections associated with
AIDS in a timely way. They must be familiar with the latest treatments, particularly those
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which allow patients to be treated at home or at subacute care facilities.
Subacute levels of care— including skilled nursing facilities, home health care, hospice
programs, and group residences — must be developed through the utilization of new or
existing resources. Reimbursements must be flexible enough to make such facilities eco-
nomically feasible.
Target specific medical care providersfor assistance. Those institutions or insurers
which provide the greatest amounts of unreimbursed care must be identified, and subsi-
dies must be provided to enable the continued delivery of these services. Owing to mat-
ters of geography, philosophy, or reputation or to referral networks, certain institutions
are likely to care for disproportionately high numbers of AIDS patients who are uninsured
or underinsured. Adequate systems must be developed to determine who is being dispro-
portionately impacted as well as the extent of shortfalls related to AIDS care. Accurate
assessments of the extent of unreimbursed care will assure the most cost-effective distri-
butions of subsidies or program funds.
Strengthen AIDS education. Education about AIDS must be strengthened to prevent
new cases. While our projections through 1991 indicate a situation that appears to be
economically manageable, worst case scenarios through 1995 and beyond may present a
far less manageable situation. Reducing the number of new infections and thereby reduc-
ing the number of new AIDS cases is an important and extremely cost-effective strategy.
Conclusion
The cost of treating people with AIDS, estimated to be more than $500 million for cases
diagnosed in New England over the ten-year period 1981 to 1991 , is an increasing burden
for society and especially for the health care industry. However, this cost is only a small
percentage of overall health care costs and, with proper planning, can be managed.
The largest component ofAIDS health care costs is acute inpatient care, and the largest
part of inpatient care costs consists of room and board. Ambulatory care and home care
are significantly less expensive alternatives.
Paying for AIDS is made more difficult by the patchwork nature of the current health
care reimbursement system and distribution of services. Many persons with AIDS are
uninsured or underinsured, or may lose their insurance coverage during the course of
their illness. Various strategies may be implemented to maintain or perhaps expand insur-
ance coverage for people with AIDS. However, insurers, including Medicare and Medi-
caid, will oppose any plan that increases their share of AIDS coverage.
Particular insurers or health care providers may find themselves overburdened as they
become the primary care centers for AIDS patients. Public and teaching hospitals in New
England are likely to be burdened the most by the AIDS epidemic.
To guard against the deterioration of health care services for people with AIDS, the
authors recommend reduction of acute inpatient care through the development of alterna-
tive levels of care, including subacute care, skilled nursing facilities, hospice programs,
group residences, and home health care; the development of targeted subsidies or pro-
grams to relieve severe pressures on particular insurers or health care providers; and the
strengthening of education to slow the growth of the AIDS epidemic. %#
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